Aurigon GmbH

HalioDx is an immuno-oncology diagnostic company providing oncologists and drug development organizations with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Leveraging the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring solutions including its flagship Immunoscore® assay for the assessment of the immune contexture of a tumor, as a key determinant of patients’ outcomes and response to cancer treatments.

HalioDx has developed a unique Biopharma partnering ecosystem for the identification of clinically relevant biomarker signatures, the demonstration of their clinical utility in trials and the development and commercialization of resulting diagnostic or companion diagnostic tests. Our programs draw on our expertise and focus on immuno-oncology, a complete suite of genomic and proteomic biomarker profiling services, a world-class data analysis and biostatistics platform, and CLIA-certified laboratories with compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. HalioDx has rapidly become the preferred partner of Biopharma developing therapeutic antibodies, vaccines, chemotherapies, oncolytic peptides, and CAR-T cell therapies.

About Immunoscore®
Immunoscore® is an in vitro diagnostic test measuring the host immune response at the tumor site. It provides a robust, precise, quantitative, and consensus assessment of lymphocytic infiltration and has been shown to predict patient outcome and response to therapies in several indications.
Immunoscore® was included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localized Colon Cancer.
Immunoscore® is commercially available in more than 20 countries.

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

PharSafer® is a niche CRO and Pharmacovigilance & Medical Services specialist.

PharSafer® provides tailored solutions to act as a complete Pharmacovigilance, Cosmetovigilance and Medical Services department. PharSafer® is able to perform all of the activities expected of in-house Pharmacovigilance and Medical Information departments in order to be compliant with the necessary legislation, providing quality information to healthcare professionals and patients, and ensuring that the company achieves a high performance service at the point at which it's needed.

PharSafer® was founded in 2002 and has continued to celebrate year on year growth and subsequent expansion since. Headquartered in the United Kingdom, PharSafer® is a privately-owned company and has offices in both the UK and Middle East, and has additional plans for offices around the world. Clients range from major pharmaceutical companies through to niche biotechnology companies and span across 7 continents. PharSafer®, in conjunction with its sister company SaPhar, is one of the most effective training organisations in the Pharmacovigilance and Medical Services field for drug companies, including medical devices and vaccines.

PharSafer are always looking to add talented Pharmacovigilance & Medical Information Professionals, Physicians, Quality Assurance Associates, Pharmacovigilance Administration personnel and IT Computer Programmers to the team. If you are interested in joining us, take a look at the PharSafer website for a list of current vacancies - http://www.pharsafer.com/about-us/work-with-us/

Altogether, we are PharSafer.

Draconis Pharma is a company mainly focused on the research of immunological response and the new therapies for the treatment of immune-based diseases such as inflammation, autoimmunity, allergy and related diseases (cancer, pain, etc).
Draconis offers experimental services in the early stages of discovery and pre-clinical research to pharmaceutical, biotechnological and food companies. Draconis’ scientific expertise guarantees highly customized solutions to evaluate, the efficacy, safety and toxicology of many types of compounds, such as small molecules, proteins, antibodies, RNA-based compounds, vaccines, functional foods or probiotics, in a wide range of target and disease experimental models.
Draconis has developed an own pipeline as a result of its R&D collaborations.

EirGen Pharma, a subsidiary of OPKO Health Inc., was established in 2005 and employs over 200 people at two sites in Waterford, Ireland. Voted Irish Pharma company of the year (SME) in 2017 EirGen produces and supplies various pharmaceutical products globally, including those required for cancer treatment. OPKO is a publically traded healthcare company involved in the discovery, development, and commercialization of next-generation diagnostics, pharmaceuticals, and vaccines. EirGen Pharma R&D - an OPKO company, our Research & Development facility opened in June 2017.